Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
McKesson
Colorcon

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 8,663,194

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,663,194
Title:Intraocular drug delivery device and associated methods
Abstract: The present invention provides devices, systems, and methods for delivery of an active agent into the eye of a subject. In one aspect, for example, an ocular active agent delivery device (10) can include an active agent reservoir (14) disposed in an annular housing (12), the annular housing (12) being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule. The device (10) can further include a semipermeable membrane (16) operatively coupled to the active agent reservoir (14), where the semipermeable membrane (16) is configured to allow diffusion of an active agent from the active agent reservoir (14). Additionally, a valve (18) can be operatively coupled to the active agent reservoir (14), where the valve (18) is configured to allow filling of the active agent reservoir (14) with an active agent.
Inventor(s): Ambati; Balamurali K. (Sandy, UT), Gale; Bruce K. (Taylorsville, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Application Number:12/945,428
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,663,194
Patent Claims:see list of patent claims

Details for Patent 8,663,194

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2028-05-12
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2006-06-30 ⤷  Free Forever Trial 2028-05-12
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2012-08-10 ⤷  Free Forever Trial 2028-05-12
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2016-10-13 ⤷  Free Forever Trial 2028-05-12
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 2018-03-20 ⤷  Free Forever Trial 2028-05-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKesson
Moodys
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.